10-Q quarterly report · filed Nov 9, 2026

Trevi Therapeutics, Inc. (TRVI) Q3 2026 10-Q Quarterly Report

Short answer

Trevi Therapeutics, Inc. (TRVI) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$21M
−81.8% YoY · −20.5% QoQ
EPS (diluted)
−$0.13
−62.5% YoY · −8.3% QoQ

Source: XBRL data from the Trevi Therapeutics, Inc. (TRVI) Q3 2026 10-Q on SEC EDGAR. USD.

Trevi Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, reflecting no product sales since inception
  • Net loss $21.5M vs $11.8M YoY, operating loss $24.5M vs $13.9M
  • R&D expense $19.1M vs $10.1M, driven by OCEAN-1, LAKE and OCEAN-2 trials
  • Cash, equivalents and marketable securities $299.4M; operating cash use $53.8M
  • April offering net proceeds $162.3M; additional funding needed for development and commercialization

Risk Factors

  • No material risk-factor changes disclosed from the 2025 Form 10-K
  • Clinical development risk: Haduvio remains investigational, with clinical trial outcomes determining advancement
  • Operational risk: outsourced CRO and manufacturing arrangements may require termination-cost payments
  • Supply-chain risk: Par Health supplied approximately $2.5 million of active pharmaceutical ingredient during the quarter
  • Financial risk: marketable securities totaled $271.559 million, including $1.502 million of unrealized losses

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Trevi Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.